The latest news:

• Centers for Medicare and Medicaid Services (CMS) Has Established Permanent Billing Codes for the NovoTTF-100A System™         Medicare has created 2new billing codes for the Novocure system...  this  is  a major step towards getting this new brain tumor treatment  covered by more insurances.
  



• Novocure to Present Fifteen Abstracts Describing Latest Aspects of NovoTTF Therapy at the 4thQuadrennial Meeting of the World Federation of Neuro-Oncology (WFNO)        15  abstracts were presented at this meeting, most from researchers not  connected to the company that makes the device.  That is a great sign that this new treatment modality is becommoing accepted by the mainstream brain tumor community. Although the  system has been approved by the FDA  in2011 to treat recurrent GBMs, and is listed  as the standard of care in the NCCN guidelines for treatment of recurrent  glioblastoma,some  treatment centers have been slow to  use the device.  Now over 110  centers  in  the USA use it!
  



• ImmunoCellular Therapeutics Phase II Study Demonstrates That Glioblastoma Patients Live Longer Without Disease Progression When Treated With ICT-107        I was hoping there would be more of a difference, like the phase 1 trial showed  (that trial showed a 50% 5 year survival). However, there were no side effects, and it is a simple shot in the arm, and it did increase progression free survival by 2 or 3 months.  We do not have all of the details yet so there may be some subgroups that did benefit a lot. 
  



• Study finds two distinct subtypes in pediatric diffuse intrinsic pontine gliomas        Excellent work.. Identifying the pathways involved is the first step toward the cure. THis was another research project that was funded by the Musella Foundation!
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants